ABVC BioPharma Provides Vitargus® Update – Phase II Vitargus® Study Protocol Received Thai FDA Approval

November 17, 2022

https://www.globenewswire.com/news-release/2022/11/17/2558195/0/en/ABVC-BioPharma-Provides-Vitargus-Update-Phase-II-Vitargus-Study-Protocol-Received-Thai-FDA-Approval.html

FREMONT, CA, Nov. 17, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that the Vitargus® Phase II Clinical Study Protocol has been approved by the Thailand Food and Drug Administration (FDA). Import licenses for the Vitargus medical device and SF6-Gas used as a comparator in the clinical study were issued to both TH001 and TH002 study sites in Thailand on November 2, 2022.

Read more at globenewswire.com

Related news for (ABVC)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.